Components of the metabolic syndrome in long-term survivors of testicular cancer

• Published in: Annals of Oncology
• Main Authors: Haugnes, H. S., Aass, N., Fosså, S. D., Dahl, O., Klepp, O., Wist, E. A., Svartberg, J., Wilsgaard, T., Bremnes, R. M.
• Format: Text
• Language: English
• Published: Oxford University Press 2006
• Subjects: original article; Tromsø
• Online Access: http://annonc.oxfordjournals.org/cgi/content/short/mdl372v1; https://doi.org/10.1093/annonc/mdl372

Background: A possible explanation of the excess cardiovascular risk in testicular cancer (TC) survivors is development of metabolic syndrome. The association between metabolic syndrome and TC treatment is examined in long-term survivors. Patients and methods: In a national follow-up study (1998-2002), 1463 TC survivors (diagnosed 1980-1994) participated. Patients >60 years were excluded in the present study, leaving 1135 patients eligible. The patients were divided in four treatment groups: surgery ( n = 225); radiotherapy ( n = 446) and two chemotherapy groups: cumulative cisplatin dose (Cis) ≤850 mg ( n = 376) and Cis >850 mg ( n = 88). A control group consisted of 1150 men from the Tromsø Population Study. Metabolic syndrome was defined according to a modified National Cholesterol Education Program definition. Results: Both chemotherapy groups had increased odds for metabolic syndrome compared with the surgery group, highest for the Cis >850 group [odds ratio (OR) 2.8, 95% confidence interval (CI) 1.6-4.7]. Also, the Cis >850 group had increased odds (OR 2.1, 95% CI 1.3-3.4) for metabolic syndrome compared with the control group. The association between metabolic syndrome and the Cis >850 group was strengthened after adjusting for testosterone, smoking, physical activity, education and family status. Conclusion: TC survivors treated with cisplatin-based chemotherapy have an increased risk of developing metabolic syndrome compared with patients treated with other modalities or with controls.